Ixekizumab May Improve Renal Function in Psoriasis
Abstract
1. Introduction
2. Case Description
3. Discussion
4. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Dattola, A.; Silvestri, M.; Bennardo, L.; Del Duca, E.; Longo, C.; Bianchi, L.; Nisticò, S. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol. Ther. 2018, 31, e12728. [Google Scholar] [CrossRef]
- Passante, M.; Dastoli, S.; Nisticò, S.P.; Bennardo, L.; Patruno, C. Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: A case report. Dermatol. Ther. 2020, 33, e13170. [Google Scholar] [CrossRef]
- Iannone, L.F.; Bennardo, L.; Palleria, C.; Roberti, R.; De Sarro, C.; Naturale, M.D.; Dastoli, S.; Donato, L.; Manti, A.; Valenti, G.; et al. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS ONE 2020, 15, e0241575. [Google Scholar] [CrossRef]
- Kamiya, K.; Kishimoto, M.; Sugai, J.; Komine, M.; Ohtsuki, M. Risk factors for the development of psoriasis. Int. J. Mol. Sci. 2019, 20, 4347. [Google Scholar] [CrossRef]
- Wild, J.; Hobohm, L.; Münzel, T.; Wenzel, P.; Steinbrink, K.; Karbach, S.; Keller, K. Psoriasis and its impact on in-hospital outcome in patients hospitalized with acute kidney injury. J. Clin. Med. 2020, 9, 3004. [Google Scholar] [CrossRef]
- Frantz, T.; Wright, E.G.; Balogh, E.A.; Cline, A.; Adler-Neal, A.L.; Feldman, S.R. Topical and oral therapies for childhood atopic dermatitis and plaque psoriasis. Children 2019, 6, 125. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.-H.; Lin, C.-C.; Tung, Y.-T.; Chao, Y.-H.; Huang, W.-C.; Lee, P.-Y. Combination therapy of acarbose and cyclosporine a ameliorates imiquimod-induced psoriasis-like dermatitis in mice. Molecules 2020, 25, 1822. [Google Scholar] [CrossRef]
- Verbenko, D.A.; Karamova, A.E.; Artamonova, O.G.; Deryabin, D.G.; Rakitko, A.; Chernitsov, A.; Krasnenko, A.; Elmuratov, A.; Solomka, V.S.; Kubanov, A.A. Apremilast pharmacogenomics in russian patients with moderate-to-severe and severe psoriasis. J. Pers. Med. 2021, 11, 20. [Google Scholar] [CrossRef] [PubMed]
- Kourakis, S.; Timpani, C.; De Haan, J.B.; Gueven, N.; Fischer, D.; Rybalka, E. Dimethyl fumarate and its esters: A drug with broad clinical utility? Pharmaceuticals 2020, 13, 306. [Google Scholar] [CrossRef] [PubMed]
- Zdanowska, N.; Owczarczyk-Saczonek, A.; Czerwińska, J.; Nowakowski, J.; Kozera-Żywczyk, A.; Owczarek, W.; Zdanowski, W.; Placek, W. Methotrexate and adalimumab decrease the serum levels of cardiovascular disease biomarkers (VCAM-1 and E-Selectin) in plaque psoriasis. Medicina 2020, 56, 473. [Google Scholar] [CrossRef] [PubMed]
- Roberti, R.; Iannone, L.F.; Palleria, C.; De Sarro, C.; Spagnuolo, R.; Barbieri, M.A.; Vero, A.; Manti, A.; Pisana, V.; Fries, W.; et al. Safety profiles of biologic agents for inflammatory bowel diseases: A prospective pharmacovigilance study in Southern Italy. Curr. Med. Res. Opin. 2020, 36, 1457–1463. [Google Scholar] [CrossRef] [PubMed]
- Muñoz-Aceituno, E.; Martos-Cabrera, L.; Ovejero-Benito, M.; Reolid, A.; Abad-Santos, F.; Daudén, E. Pharmacogenetics update on biologic therapy in psoriasis. Medicina 2020, 56, 719. [Google Scholar] [CrossRef] [PubMed]
- Tokuyama, M.; Mabuchi, T. New treatment addressing the pathogenesis of psoriasis. Int. J. Mol. Sci. 2020, 21, 7488. [Google Scholar] [CrossRef]
- Kim, H.W.; Lee, C.-K.; Chang-Keun, L.; Choe, J.-Y.; Park, E.-J.; Kim, J. Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol. Int. 2014, 35, 727–734. [Google Scholar] [CrossRef] [PubMed]
- Maghfour, J.; Elliott, E.; Gill, F.; Brittany, S.; Andrea, M.; Stumpf, B.; Murina, A. Effect of biologic drugs on renal function in psoriasis patients with chronic kidney disease. J. Am. Acad. Dermatol. 2020, 82, 1249–1251. [Google Scholar] [CrossRef]
- Marchant, V.; Tejera-Muñoz, A.; Marquez-Expósito, L.; Rayego-Mateos, S.; Rodrigues-Diez, R.R.; Tejedor, L.; Santos-Sanchez, L.; Egido, J.; Ortiz, A.; Valdivielso, J.M.; et al. IL-17A as a potential therapeutic target for patients on peritoneal dialysis. Biomolecules 2020, 10, 1361. [Google Scholar] [CrossRef]
- Summers, S.A.; Steinmetz, O.M.; Li, M.; Kausman, J.Y.; Semple, T.; Edgtton, K.L.; Borza, D.-B.; Braley, H.; Holdsworth, S.R.; Kitching, A.R. Th1 and Th17 cells induce proliferative glomerulonephritis. J. Am. Soc. Nephrol. 2009, 20, 2518–2524. [Google Scholar] [CrossRef] [PubMed]
- Dastoli, S.; Iannone, L.F.; Bennardo, L.; Silvestri, M.; Palleria, C.; Nisticò, S.P.; De Sarro, G.; Russo, E. A Rare case of drug-induced erectile dysfunction with secukinumab solved after switch to ixekizumab in a psoriatic patient: A case report. Curr. Drug Saf. 2020, 15, 69–72. [Google Scholar] [CrossRef]
- Dattola, A.; Silvestri, M.; Tamburi, F.; Amoruso, G.F.; Bennardo, L.; Nisticò, S.P. Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising. Dermatol. Ther. 2020, 33, e14504. [Google Scholar] [CrossRef]
- Nogueira, E.; Hamour, S.; Sawant, D.; Henderson, S.; Mansfield, N.; Chavele, K.-M.; Pusey, C.D.; Salama, A.D. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol. Dial. Transpl. 2010, 25, 2209–2217. [Google Scholar] [CrossRef]
- Holdswoth, S.; Gan, P.; Kitching, A. Biologics for the treatment of autoimmune renal diseases. Nat. Rev. Nephrol. 2016, 12, 217–231. [Google Scholar] [CrossRef] [PubMed]
- Zickert, A.; Amoudruz, P.; Sundström, Y.; Rönnelid, J.; Malmström, V.; Gunnarsson, I. IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment. BMC Immunol. 2015, 16, 7. [Google Scholar] [CrossRef] [PubMed]
- Wen, Y.; Crowley, S.D. Renal effects of cytokines in hypertension. Curr. Opin. Nephrol. Hypertens. 2018, 27, 70–76. [Google Scholar] [CrossRef] [PubMed]
- Ma, J.; Li, Y.J.; Chen, X.; Kwan, T.; Chadban, S.J.; Wu, H. Interleukin 17A promotes diabetic kidney injury. Sci. Rep. 2019, 9, 2264. [Google Scholar] [CrossRef]
- Orejudo, M.; Rodriguez-Diaz, R.; Rodriguez-Diaz, R.; Garcia-Redondo, A.; Santos-Sanchez, L.; Randez-Garbayo, J.; Cannata-Ortiz, P.; Ramos, A.M.; Ortiz, A.; Selgas, P.; et al. Interleukin 17A participates in renal inflammation associated to experimental and human hypertension. Front. Pharmacol. 2019, 10, 1015. [Google Scholar] [CrossRef] [PubMed]
- Lavoz, C.; Rayego-Mateos, S.; Orejudo, M.; Opazo-Ríos, L.; Marchant, V.; Marquez-Exposito, L.; Tejera-Muñoz, A.; Navarro-González, J.F.; Droguett, A.; Ortiz, A.; et al. Could IL-17A be a novel therapeutic target in diabetic nephropathy? J. Clin. Med. 2020, 9, 272. [Google Scholar] [CrossRef]
- Lavoz, C.; Sánchez Matus, Y.; Orejudo, M.; Carpio, J.D.; Droguett, A.; Egido, J.; Mezzano, S.; Ruiz-Ortega, M. IL-17A blockade improves proteinuria and renal lesions in an accelerated model of diabetic nephropathy. Kidney Int. 2019, 95, 1418–1432. [Google Scholar] [CrossRef]
- Koike, Y.; Fujiki, Y.; Higuchi, M.; Fukuchi, R.; Kuwatsuka, S.; Murota, H. An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. JAAD Case Rep. 2019, 5, 150–152. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Amoruso, G.F.; Nisticò, S.P.; Iannone, L.; Russo, E.; Rago, G.; Patruno, C.; Bennardo, L. Ixekizumab May Improve Renal Function in Psoriasis. Healthcare 2021, 9, 543. https://doi.org/10.3390/healthcare9050543
Amoruso GF, Nisticò SP, Iannone L, Russo E, Rago G, Patruno C, Bennardo L. Ixekizumab May Improve Renal Function in Psoriasis. Healthcare. 2021; 9(5):543. https://doi.org/10.3390/healthcare9050543
Chicago/Turabian StyleAmoruso, Giuseppe Fabrizio, Steven Paul Nisticò, Luigi Iannone, Emilio Russo, Giuseppe Rago, Cataldo Patruno, and Luigi Bennardo. 2021. "Ixekizumab May Improve Renal Function in Psoriasis" Healthcare 9, no. 5: 543. https://doi.org/10.3390/healthcare9050543
APA StyleAmoruso, G. F., Nisticò, S. P., Iannone, L., Russo, E., Rago, G., Patruno, C., & Bennardo, L. (2021). Ixekizumab May Improve Renal Function in Psoriasis. Healthcare, 9(5), 543. https://doi.org/10.3390/healthcare9050543